![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, August 05, 2013 12:41:48 PM
http://ih.advfn.com/p.php?pid=nmona&article=58685491
Court Upholds $48.6 Million Jury Award to Enzo Biochem
Alert
Enzo Biochem (NYSE:ENZ)
Intraday Stock Chart
Today : Monday 5 August 2013
Click Here for more Enzo Biochem Charts.
Enzo Biochem Inc. (NYSE:ENZ) reported today that a Federal Court Judge in New Haven, CT, has upheld the jury verdict issued in November 2012 which awarded Enzo $48.6 million in direct infringement damages as a result of Applera Corp., now Life Technologies, Inc. (NASDAQ:LIFE) having infringed Enzo’s patent covering pioneering technologies relating to compounds used in DNA sequencing systems to read the genetic code. The judge’s ruling opens the way for Enzo’s recovery of prejudgment interest on the damages award, which should exceed $25 million in addition to the judgment.
The Enzo action is entitled Enzo Biochem, Inc. et al. vs. Applera Corp. and Tropix Inc. in New Haven, CT Civil Action No. 3:04cv929 (JBA).
“We are pleased with the Judge’s decision which, in addition to the monetary award, we anticipate will have a positive impact on the resolution of pending actions that Enzo brought in the U.S. Southern District Court in New York City, which involve additional defendants, patents and contract issues,” said Barry Weiner, Enzo President.
In addition to leaving the jury verdict undisturbed, the Judge also denied Life Technologies’ request for a finding that Enzo’s infringement claims are barred by laches and/or equitable estoppel, as well as its motion for a new trial and denied Enzo’s request for reconsideration seeking additional damages.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of health care both today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses are dependent on a number of factors outside of the control of the company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2012. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
Recent ENZ News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:15:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 09:23:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 09:22:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 11:50:46 PM
- Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update • GlobeNewswire Inc. • 06/13/2024 08:20:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/13/2024 08:15:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 08:46:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:44:15 PM
- Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update • GlobeNewswire Inc. • 03/13/2024 08:26:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 12:22:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:20 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:23:21 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 02:35:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:02:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:01:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2024 02:00:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:33:19 PM
- Form DEFR14A - Revised definitive proxy soliciting materials • Edgar (US Regulatory) • 12/21/2023 09:48:46 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 12/21/2023 09:15:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/15/2023 09:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:01:19 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 11/28/2023 10:16:15 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/03/2023 09:07:13 PM
FEATURED Element79 Gold Corp Appoints Warren Levy to Board of Directors • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM